IRIS Accounts Production v24.3.0.553 11368668 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh113686682023-03-31113686682024-03-31113686682023-04-012024-03-31113686682022-03-31113686682022-04-012023-03-31113686682023-03-3111368668ns15:EnglandWales2023-04-012024-03-3111368668ns14:PoundSterling2023-04-012024-03-3111368668ns10:Director12023-04-012024-03-3111368668ns10:Director22023-04-012024-03-3111368668ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3111368668ns10:SmallEntities2023-04-012024-03-3111368668ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3111368668ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3111368668ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3111368668ns10:FullAccounts2023-04-012024-03-311136866812023-04-012024-03-3111368668ns10:RegisteredOffice2023-04-012024-03-3111368668ns5:CurrentFinancialInstruments2024-03-3111368668ns5:CurrentFinancialInstruments2023-03-3111368668ns5:Non-currentFinancialInstruments2024-03-3111368668ns5:Non-currentFinancialInstruments2023-03-3111368668ns5:ShareCapital2024-03-3111368668ns5:ShareCapital2023-03-3111368668ns5:RetainedEarningsAccumulatedLosses2024-03-3111368668ns5:RetainedEarningsAccumulatedLosses2023-03-3111368668ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3111368668ns5:PlantMachinery2023-04-012024-03-3111368668ns5:IntangibleAssetsOtherThanGoodwill2023-03-3111368668ns5:IntangibleAssetsOtherThanGoodwill2024-03-3111368668ns5:IntangibleAssetsOtherThanGoodwill2023-03-3111368668ns5:PlantMachinery2023-03-3111368668ns5:PlantMachinery2024-03-3111368668ns5:PlantMachinery2023-03-3111368668ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3111368668ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 11368668 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

FOR

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: Dr N B Broughton
Mrs L.S. Sharp





REGISTERED OFFICE: Second Floor South
The Fitted Rigging House
Anchor Wharf, The Historic Dockyard
Chatham
Kent
ME4 4TZ





REGISTERED NUMBER: 11368668 (England and Wales)





ACCOUNTANTS: Carleys
Second Floor South
The Fitted Rigging House
The Historic Dockyard
Chatham
Kent
ME4 4TZ

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 150,821 167,813
Tangible assets 5 3,905 7,069
154,726 174,882

CURRENT ASSETS
Debtors 6 35,117 70,607
Cash at bank 354,639 52,923
389,756 123,530
CREDITORS
Amounts falling due within one year 7 251,749 162,633
NET CURRENT ASSETS/(LIABILITIES) 138,007 (39,103 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

292,733

135,779

CREDITORS
Amounts falling due after more than one
year

8

(4,121

)

(15,982

)

PROVISIONS FOR LIABILITIES (976 ) (1,767 )
NET ASSETS 287,636 118,030

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 287,536 117,930
SHAREHOLDERS' FUNDS 287,636 118,030

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 October 2024 and were signed on its behalf by:




Mrs L.S. Sharp - Director



Dr N B Broughton - Director


ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024


1. STATUTORY INFORMATION

Ethos Pharmaceutical Ethics And Compliance Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Development expenditure is written off to the profit and loss account in the year in which it is incurred, unless the directors are satisfied as to the technical, commercial and financial viability on specific projects. In this situation, the expenditure is capitalised and amortised using the straight-line method over the period during which the company is expected to benefit.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - Straight line over 3 years

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 2 ) .

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 April 2023
and 31 March 2024 169,938
AMORTISATION
At 1 April 2023 2,125
Charge for year 16,992
At 31 March 2024 19,117
NET BOOK VALUE
At 31 March 2024 150,821
At 31 March 2023 167,813

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2023 10,792
Disposals (1,664 )
At 31 March 2024 9,128
DEPRECIATION
At 1 April 2023 3,723
Charge for year 3,151
Eliminated on disposal (1,651 )
At 31 March 2024 5,223
NET BOOK VALUE
At 31 March 2024 3,905
At 31 March 2023 7,069

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 21,016 47,561
Other debtors 14,101 23,046
35,117 70,607

ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 4,553 5,066
Trade creditors 23,992 12,160
Amounts owed to group undertakings 3,893 94,973
Amounts owed to associates - 23,760
Taxation and social security 104,663 19,019
Other creditors 114,648 7,655
251,749 162,633

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Bank loans 4,121 15,982

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

During the year the company advanced a loan to a director totalling £57 (2023: £Nil) and received repayments totalling £Nil (2023: £Nil). The loan outstanding at the balance sheet date totalled £57 (2023: £Nil). The loan was repaid after the year end.

10. RELATED PARTY DISCLOSURES

As at the balance sheet date the company owed its parent company, Green Bear Medical Limited, £3,893 (2023: £94,973) and an associated company nil (2023: £23,760).

11. ULTIMATE CONTROLLING PARTY

The ultimate parent company and controlling party is Green Bear Medical Limited, a company registered in England and Wales.